Colorectal cancer

  title={Colorectal cancer},
  author={David Cunningham and Wendy S. Atkin and Heinz-Josef Lenz and Henry T. Lynch and Bruce D. Minsky and Bernard Nordlinger and Naureen Starling},
  journal={The Lancet},

Figures and Tables from this paper

Microsatellite instability & survival in patients with stage II/III colorectal carcinoma
MSI-H CRCs had a lower recurrence rate, but the prognosis was worse following adjuvant 5-FU therapy, and multi- and univariate Cox regression analysis failed to show a difference between MSI-H and MSS groups with respect to disease-free, disease-specific and overall survival.
Delivery of Personalized Care for Locally Advanced Rectal Cancer: Incorporating Pathological, Molecular Genetic, and Immunological Biomarkers Into the Multimodal Paradigm
The current multidisciplinary context in which LARC care should be delivered is outlined and how some key prognosticators, including novel histopathological, molecular genetics, and immunological biomarkers might fit into the wider context of personalized LARC management in the coming years are discussed.
Managing advanced colorectal cancer: have we reached the PEAK with current therapies?
  • B. WolpinA. Bass
  • Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2014
The primary result of this trial does not suggest a difference in controlling disease progression for one regimen versus the other in the primary analysis population, and further results of interest are provided in secondary analyses.
Risk Factors of Tumour Recurrence and Reduced Survival in Rectal Cancer
Analysis of potential risk factors of tumour recurrence and reduced survival in a cohort of patients registered in the SRCR between 1995 and 1997 with 5-year follow-up in Sweden suggests high immunohistochemical expression of the tumour marker ezrin in primary tumours from patients with LR correlated to earlier occurrence of LR.
Changing concepts and trends in rectal cancer patients
MR based TA of rectal cancers can predict outcome before undergoing surgery and could potentially select patients with predicted poor prognosis for personalized intensive therapy.
Metastatic Colorectal Cancer and the Need for More Endoscopic Tools
A 48-year-old man with stage IVB sigmoid adenocarcinoma diagnosed in 2007 treated with five different lines of adjuvant chemotherapy, right lobectomy for liver metastasis, and video-assisted thoracoscopy for pulmonary metastasis presenting with jaundice and abdominal pain survived 7 years from his initial diagnosis of stage IV colorectal cancer with endoscopic and oncologic management.
AC133 expression associated with poor prognosis in stage II colorectal cancer
The data suggest that AC133 is an independent adverse prognostic factor and a potential marker for survival classification in stage II CRC patients, and high AC133 expression was identified as a significant predictor for poor disease-free survival and overall survival.
Management of rectal neoplasia in hereditary colorectal cancer patients
  • J. Ashburn
  • Medicine
    Seminars in Colon and Rectal Surgery
  • 2018
The best surgical approach considers both the primary cancer as well as the remaining unstable colorectum, and thoughtful timing of multimodal therapies helps to avoid negative effects on bowel reconstruction to maintain quality of life.
The role of personalized medicine in metastatic colorectal cancer: an evolving landscape
Current and emerging biomarkers are reviewed along with their roles in selecting patients for targeted treatment with currently licensed therapies and drugs being evaluated in clinical trials, and the value of predictive biomarkers of chemosensitivity and potential future treatment strategies are discussed.
Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions.
The most recent advances in development of AIs in mCRC with particular focus on aflibercept and regorafenib are described, the existing challenges for the evaluation of these agents in clinical practice and potential strategies in designing clinical trials that could lead to the discovery of clinically meaningful biomarkers are described.


Actual 10-year survival after resection of colorectal liver metastases defines cure.
In well-selected patients, there is at least a one in six chance of cure after hepatectomy for CLM, and the presence of poor prognostic factors does not preclude the possibility of long-term survival and cure.
Progress in colorectal cancer survival in Europe from the late 1980s to the early 21st century: The EUROCARE study
There is a huge potential for reducing the burden of CRC in Europe by more widespread and equal delivery of existing options of effective early detection and curative treatment to the European population.
Yield of routine molecular analyses in colorectal cancer patients ≤70 years to detect underlying Lynch syndrome
Routine use of MSI testing may be considered in colorectal cancer patients up to the age of 70 years, with a central role for the pathologist in the selection of patients.
Molecular tests for colorectal cancer screening.
An overview of the performances of DNA, RNA, and protein markers for CRC detection in stool and blood is provided and the recent boost in proteomics research leads to many new candidate protein markers.
A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy.
Factors that are associated most strongly with risk of advanced neoplasia are patient age and the number and size of prior adenomas.
Outcome of Microscopic Incomplete Resection (R1) of Colorectal Liver Metastases in the Era of Neoadjuvant Chemotherapy
In patients treated with neoadjuvant chemotherapy, R1 resection was of no predictive value for DFS and OS.
Risk Factors for Excess Mortality in the First Year After Curative Surgery for Colorectal Cancer
The 30-day mortality rate highly underestimates the risk of dying in the first year after surgery, with excess 1-year mortality rates varying from 15 to 30%.
Transanal endoscopic microsurgery for T1 rectal cancer: size matters!
Tumor size alone or in combination with submucosal invasion depth or tumor budding appeared to be a significant predictive factor for locoregional failure after TEM for T1 rectal cancer.
The reduction in colorectal cancer mortality after colonoscopy varies by site of the cancer.
In Manitoba, colonoscopies significantly reduce mortality from CRC, but the benefit is not uniform for colorectal tumors that arise in different areas of the colon.